- The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) increased over 15% pre-market. This is why it happened.
The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) – a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH) and liver disease – increased over 15% pre-market. Investors are responding positively to Hepion Pharmaceuticals announcing that it expects to release additional data from its Phase 2a ‘AMBITION’ NASH clinical trial before the market today.
And as previously disclosed, all primary endpoints were achieved in the trial.
Hepion is pleased to invite interested parties to participate in a conference call and webcast at 8:30 a.m. ET on September 13, during which the previously disclosed AMBITION topline results (as well as the additional new data) will be discussed.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.